Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Our mission is to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Participants will learn how to translate theoretical information deriving from recently completed trials of new anticoagulants in atrial fibrillation and from the recently revised 2012 ESC Atrial Fibrillation Guidelines into clinical practice.
Two challenging cases of atrial fibrillation management will be presented. Interactive discussion with the audience will lead the participant to logically choose the best treatment options for the cases. Pros and Cons of the available choices will be discussed.
Raffaele de Caterina and Gregory Lip
Focused update of the ESC Guidelines for the management of atrial fibrillation: An update of the 2010 ESC Guidelines for the management of atrial fibrillation * Developed with the special contribution of the European Heart Rhythm Association.
R. De Caterina also suggests:Anticoagulants in heart disease: current status and perspectives. Eur Heart J 2007;28:880-913.De Caterina R, Husted S, Wallentin L, Andreotti F, Arnesen H, Bachmann F, Baigent C, Huber K, Jespersen J, Kristensen SD, Lip GYH, Morais J, Rasmussen LH, Siegbahn A, Verheugt FWA, Weitz JI. New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task force on Anticoagulants in Heart Disease Position Paper. J Am Coll Cardiol 2012;59:1413-25.Lip GY, Huber K, Andreotti F, Arnesen H, Airaksinen KJ, Cuisset T, Kirchhof P, Marin F. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/ stenting. Thrombosis and haemostasis 2010;103:13-28.
This educational programme is accredited for 1 CME Credit(s). Each participant should claim only those hours of credits that have actually been spent in the educational activity.
European Society of Cardiology
European Heart HouseLes Templiers2035 Route des CollesCS 80179 BIOT
06903 Sophia Antipolis, FR
© 2017 European Society of Cardiology. All rights reserved